Preclinical Overview of Sorafenib, a Multikinase Inhibitor That Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-08-0013
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Receptor Tyrosine Kinase (RTK); VEGF-A

Science-Business eXchange
2014English

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

Journal of Clinical Pharmacology
Pharmacology
2018English

Viral Oncolysis That Targets Raf-1 Signaling Control of Nuclear Transport

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
2009English

Preclinical Antitumor Activity of BMS-599626, a Pan-Her Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling

Clinical Cancer Research
Cancer ResearchOncology
2006English

Sorafenib, a Dual Raf Kinase/Vascular Endothelial Growth Factor Receptor Inhibitor Has Significant Anti-Myeloma Activity and Synergizes With Common Anti-Myeloma Drugs

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

Lymphangioleiomyomatosis--Presence of Receptor Tyrosine Kinases and the Angiogenesis Factor VEGF-A as Potential Therapeutic Targets

Thorax
PulmonaryRespiratory Medicine
2007English

Impact of Adding the Multikinase Inhibitor Sorafenib to Endocrine Therapy in Metastatic Estrogen Receptor-Positive Breast Cancer

Future Oncology
MedicineCancer ResearchOncology
2014English

Downregulation of Sef, an Inhibitor of Receptor Tyrosine Kinase Signaling, Is Common to a Variety of Human Carcinomas

Oncogene
Cancer ResearchGeneticsMolecular Biology
2007English

Tyrosine Kinase Inhibitor and Target Therapy

2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy